Pancreatic Cancer Research

ResearcherSt John of God Subiaco HospitalActive in the last 2 years

Andrew Peter Dean

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6632-2799; OpenAlex author ID A5052709676, A5110871822, A5110948338. Sources: OpenAlex.

Their work

Papers
14 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
47
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper · 2023: 5 papers · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 14

  1. Breakthrough Pediococcus acidilactici and Leuconostoc lactis bacteraemia with elevated meropenem minimum inhibitory concentrations during broad-spectrum antimi… Co-author DOI 10.1016/j.idcr.2026.e02692↗
  2. A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3). Co-author DOI 10.1080/14796694.2025.2458458↗
  3. ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenoc… First author DOI 10.1016/j.esmogo.2023.07.001↗
  4. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-lab… Co-author DOI 10.1016/s0140-6736(23)01366-1↗
  5. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  6. Evaluation of a Clinic-Based Exercise Program in Patients with Pancreatic Cancer Undergoing Nonsurgical Treatment. Co-author DOI 10.1249/mss.0000000000003019↗
  7. Overall survival and treatment modalities in pancreatic adenocarcinoma: a retrospective analysis of a single centre in Western Australia. Last author DOI 10.21037/jgo-23-488↗
  8. Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma… Co-author DOI 10.1016/s2468-1253(22)00167-4↗
  9. Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer. Co-author DOI 10.1002/psp4.12725↗
  10. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. Last author DOI 10.1016/j.ejca.2021.03.028↗
  11. Feasibility and efficacy of a multicomponent exercise medicine programme in patients with pancreatic cancer undergoing neoadjuvant therapy (the EXPAN trial): s… Co-author DOI 10.1136/bmjgast-2021-000642↗
  12. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPO… Co-author DOI 10.1097/mpa.0000000000001455↗
  13. Gemcitabine-induced haemolytic uraemic syndrome in pancreatic adenocarcinoma. First author DOI 10.1136/bcr-2018-228363↗
  14. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Teresa Mercade Macarulla · 5 shared papers, 2020–2025 · strength 0.68
  2. Zev A. Wainberg · 4 shared papers, 2021–2025 · strength 0.58
  3. Tanios Bekaii‐Saab · 4 shared papers, 2021–2025 · strength 0.58
  4. Sreenivasa Rao Chandana · 2 shared papers, 2023–2025 · strength 0.34
  5. Eileen Mary O'Reilly · 2 shared papers, 2023–2025 · strength 0.34
  6. Thorsten Oliver Goetze · 2 shared papers, 2023–2025 · strength 0.34
  7. Christelle de la Fouchardière · 2 shared papers, 2023–2025 · strength 0.34
  8. Andrew Scott Paulson · 2 shared papers, 2023–2025 · strength 0.34
  9. Roberto Pazo-Cid · 2 shared papers, 2023–2025 · strength 0.34
  10. Igor Kišš · 2 shared papers, 2023–2025 · strength 0.34
  11. Davide Melisi · 2 shared papers, 2023–2025 · strength 0.34
  12. Richard A Hubner · 2 shared papers, 2023–2025 · strength 0.34
  13. Shubham Pant · 2 shared papers, 2023–2025 · strength 0.34
  14. Eric Van Cutsem · 2 shared papers, 2023–2025 · strength 0.34
  15. Adarsh Das · 2 shared papers, 2019–2023 · strength 0.32
  16. Timothy Jay Price · 2 shared papers, 2022–2023 · strength 0.31
  17. Hao Luo · 2 shared papers, 2021–2023 · strength 0.29
  18. Dennis R. Taaffe · 2 shared papers, 2021–2023 · strength 0.29
  19. Nigel A. Spry · 2 shared papers, 2021–2023 · strength 0.29
  20. Daniel Abido Galvao · 2 shared papers, 2021–2023 · strength 0.29
  21. Arindam Chakravorty · 1 shared paper, 2026 · strength 0.29
  22. Aung Du · 1 shared paper, 2026 · strength 0.29
  23. Bin Zhang · 2 shared papers, 2021 · strength 0.24
  24. Farshid Dayyani · 2 shared papers, 2021 · strength 0.24
  25. Kabir Mody · 2 shared papers, 2021 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.